This study reported that the ExoDxTM prostate test successfully stratified patients into low- and high-grade prostate cancer risk categories, assisting physicians in making informed decisions regarding the necessity of biopsies for patients with uncertain cancer risk based on prostate specific antigen results. This evidence concerns the gene KLK3 and prostate carcinoma.